Tofacitinib downregulates JAK1 and JAK3 on human intestinal monocytes and macrophages without affecting dendritic cells phenotype or function
Tofacitinib does not modulate the phenotype and function of human intestinal cDC in UC. On the contrary, it displays a differential capacity to modulate intestinal monocyte and macrophage phenotype. Future studies should address whether it also translates into a differential function of these cells.
Authors
- Beatriz De Andrés-Asenjo (ORCID: https://orcid.org/0000-0002-2503-8932)
- Jésus Barrio (ORCID: https://orcid.org/0000-0001-7087-3921)
- Alejandro Romero (ORCID: https://orcid.org/0000-0001-5483-4973)
- Elisa Arribas‐Rodríguez (ORCID: https://orcid.org/0000-0002-4470-075X)
- Benito Velayos
- José Antonio Garrote (ORCID: https://orcid.org/0000-0003-1797-6520)
- Luis Ignacio Fernández-Salazar (ORCID: https://orcid.org/0000-0002-9951-7979)
- David Bernardo (ORCID: https://orcid.org/0000-0002-2843-6696)
- Francisco Javier García-Alonso (ORCID: https://orcid.org/0000-0003-1638-1648)
- Eduardo Arranz (ORCID: https://orcid.org/0000-0001-8994-3061)
- Álvaro Martín‐Muñoz (ORCID: https://orcid.org/0000-0002-6329-2827)
- Ángel De Prado
Institutions
- Centro de Investigación Biomédica en Red (ES)
- Instituto de Biomedicina y Genética Molecular de Valladolid (ES)
- Hospital Clínico Universitario de Valladolid (ES)
- Hospital Universitario Río Hortega (ES)
Publication Details
- Journal
- Journal of Translational Autoimmunity
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1016/j.jtauto.2025.100271
- Primary Topic
- Cytokine Signaling Pathways and Interactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer